Select bets to continue to perform

Pharmaceuticals & Biotech.

SECTOR | 29 Jul 2024

Select bets to continue to perform

buy

Pharmaceuticals & Biotech.

KRChoksey

Nifty Pharma is trading at 1-year forward PE of 34.5x vs. 22.8x for Nifty 50, indicating relatively richer valuation levels for the sector from a relative valuation’s perspective.
Nonetheless, given the strong earnings growth that we believe can be witnessed by Glenmark (42.5% CAGR), Lupin Ltd. (37.5% CAGR), and Zydus Life (16.2% CAGR) over FY24-FY26E, we consider them our preferred picks.

Axis Direct released a Sector Update report for Pharmaceuticals & Biotech. on 08 Apr, 2025.

More from Pharmaceuticals & Biotech.

Recommended

Market trades flat, Waaree Energies' net profit grows 34.1% YoY to Rs 618.9 crore in Q4

Trendlyne Marketwatch | 23 Apr 2025, 01:01PM

Five stocks to buy from analysts this week - April 22, 2025

The Baseline | 22 Apr 2025, 05:59PM

Volume-led growth, price stabilization and new US launches boost Indian pharma